Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi Wins Legal Dispute Over Zantac Links to Cancer

Sanofi Wins Legal Dispute Over Zantac Links to Cancer

27th June 2023

The healthcare division of Boehringer Ingelheim, which contains the heartburn drug Zantac, was bought by Sanofi when the two companies exchanged assets back in 2016.

Now, individuals in the US are taking legal action against BI, claiming the drug is connected to causing cancer. The firm has attempted to obtain compensation for potential future claims, but it has been denied.

At the same time, other producers of Zantac, such as GSK and Pfizer, have bolstered their legal protection. There was a case back in December where a federal judge determined that the charges made against the corporations were unfounded, invalidating almost 50,000 federal claims across a number of judicial districts.

The problem started back in 2019 when Valisure, an ecommerce pharmacy, found significant amounts of N-nitrosodimethylamine in Zantac. This raised concerns, causing the FDA to request that all manufacturers voluntarily take it off the market in 2020.

Sanofi “remains confident that the defense of the underlying U.S. Zantac litigation is very strong,” with both the European Medicines Agency and FDA, concluding that there is no proof that the ranitidine content of Zantac causes cancer.

“Tens of thousands of claimants who were once a part of this MDL litigation chose to abandon their claims or else withdrew early from the MDL, either filing in state court or not re-filing at all.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.